EUVIMED · CrossrefZeitschrift
The Lancet Diabetes & Endocrinology
ISSN 2213-8587 · Elsevier BV
Neueste Artikel
Trends in prevalence of type 2 diabetes and intermediate hyperglycaemia in Mauritius from 1987 to 2021 based on results from the oral glucose tolerance test: a repeated cross-sectional study
Presentation, management, and outcomes of ectopic Cushing syndrome: an international, multicentre, retrospective, cohort study
Correction to Lancet Diabetes Endocrinol 2026; 14: 149–56
Getting personal with hormones: the ups and the downs
Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis
Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial
Clinical and metabolic subtypes of recent-onset adult type 1 diabetes: a prospective cohort study
Oral small-molecule GLP-1 receptor agonist for obesity in people from Japan
Who should prescribe obesity management medications? An IFSO position statement
Nutritional, functional, and psychological considerations for incretin-based therapies in adults—an EASO, EFAD, and ECPO Consensus Statement
Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study
A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial
Rethinking prophylactic central neck dissection in clinically node-negative papillary thyroid cancer
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial
Burden and determinants of diabetes in sub-Saharan Africa
Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial
Diabetes-related complications: an evolving spectrum
Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study
Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study
Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic β-cell function pretransplant
3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial
Feasibility of general population screening for type 1 diabetes in the UK: the ELSA study
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial
Prediabetes remission and cardiovascular morbidity and mortality: post-hoc analyses from the Diabetes Prevention Program Outcome study and the DaQing Diabetes Prevention Outcome study
11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050
Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement
GLP-1 receptor agonists for obesity: eligibility across 99 countries
Obesity in China: current progress and future prospects
Circadian and sleep medicine: challenges and future directions for metabolic and endocrine research
EUVIMED